East Cape Onc, Cape Town, South Africa
Conrad R. Jacobs , Bernardo Leon Rapoport , Sze Wai Chan , Paul Ruff , Ana Maria Arance , Karmele Mujika , James Robert Anderson , Mallika Lala , Lokesh Jain , Omobolaji Oyekunle Akala , Elliot Chartash , Graham Lawrence Cohen
Background: In KEYNOTE-555, a model-based approach suggested expected drug exposure with pembro 400 mg Q6W is similar to that observed with approved doses of pembro 200 mg or 2 mg/kg Q3W. The pembro Q6W dose is now approved. We present interim efficacy, safety and PK of 1L pembro 400 mg Q6W for patients (pts) with advanced melanoma in KEYNOTE-555 Cohort B (NCT03665597). Methods: Eligible pts had unresectable stage III or IV melanoma, ECOG PS ≤1, and no prior systemic therapy for advanced disease.Pts received pembro 400 mg Q6W for up to 18 cycles (≈2 years).The primary efficacy endpoint was ORR per RECIST v1.1 by blinded independent central review (BICR). Secondary endpoints included PFS by BICR per RECIST v1.1 and safety. PK profile and exposure were evaluated for cycle 1 and steady state (cycle 4). Results: Between May 2019 and Jan 2020, 101 pts were enrolled and received ≥1 dose of pembro. Baseline characteristics were generally similar to pt cohorts of historical pembro studies in advanced melanoma. As of the data cutoff date of August 6, 2020, all pts had ≥6 mo of follow-up and 40.6% of pts had discontinued study treatment. Median (range) duration of treatment and doses administered were 8.2 mo (1 day–13.9 mo) and 6 (1–11) doses, respectively. Observed exposure with pembro 400 mg Q6W had lower variability than model predictions and was within PK parameters from clinical experience with other pembro regimens (Table). ORR was 50.5% (95% CI 40.4–60.6). 12.9% of pts had CR and 37.6% had PR. Median PFS was 13.8 mo (95% CI 3.0–not reached). Estimated PFS rates were 56.5% at 6 mo and 54.3% at 12 mo. Treatment-related AEs of any grade occurred in 79.2% of pts (grade 3–4: 6.9% of pts; no deaths due to a treatment-related AE). The most common immune-mediated AEs were hyperthyroidism (6.9%) and hypothyroidism (6.9%). Conclusions: 1L treatment with pembro 400 mg Q6W yielded a clinically meaningful ORR in pts with advanced melanoma. PK, efficacy and safety results from KEYNOTE-555 Cohort B support prior findings from the model-based assessment and indicate that the benefit-risk profile for the more practical pembro 400 mg Q6W regimen is consistent with that of 200 mg or 2 mg/kg Q3W regimens. Clinical trial information: NCT03665597
PK metrics; data shown as geometric mean (μg/mL) and 95% CI. | |||||
---|---|---|---|---|---|
400 mg Q6W Cohort Ba | 400 mg Q6W model-predictedb | 200 mg Q3Wc | 2 mg/kg Q3Wc | 10 mg/kg Q2Wc | |
Cycle 1 | |||||
Cmin | 15.1 13.5–16.9 | 10.6 10.4–10.8 | 18.1 17.8–18.3 | 13.5 13.3–13.6 | 119.0 117.1–120.6 |
Cmax | 127.0 121.3–132.7 | 123.0 121.6–124.3 | 59.1 58.5–59.7 | 44.1 43.7–44.5 | 220.3 217.8–222.7 |
Steady state | |||||
Cmin | 24.0 20.6–27.9 | 20.3 19.8–20.9 | 30.9 30.5–31.4 | 23.1 22.7–23.4 | 197.1 193.4–200.2 |
Cmax | 150.0 141.9–158.3 | 147.5 146.1–149.4 | 92.8 91.7–94.1 | 69.2 68.4–70.2 | 428.2 424.0–433.2 |
aObserved data. bSimulated using a reference population PK model not including KEYNOTE-555 Cohort B. cSimulated using a reference population PK model based on dataset of 2993 pts from KEYNOTE-001, 002, 006, 010, and 024.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Daniel Olson
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Richard S. Finn
2021 ASCO Annual Meeting
First Author: Jun Guo
2023 ASCO Breakthrough
First Author: Akshit Chitkara